| International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies DJ Angiolillo, F Rollini, RF Storey, DL Bhatt, S James, DJ Schneider, ... Circulation 136 (20), 1955-1975, 2017 | 391 | 2017 |
| Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention D Capodanno, R Mehran, M Valgimigli, U Baber, S Windecker, P Vranckx, ... Nature Reviews Cardiology 15 (8), 480-496, 2018 | 200 | 2018 |
| Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease DJ Angiolillo, JA Jakubowski, JL Ferreiro, A Tello-Montoliu, F Rollini, ... Journal of the American College of Cardiology 64 (10), 1005-1014, 2014 | 196 | 2014 |
| Switching P2Y12-receptor inhibitors in patients with coronary artery disease F Rollini, F Franchi, DJ Angiolillo Nature Reviews Cardiology 13 (1), 11-27, 2016 | 175 | 2016 |
| Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis M Galli, S Benenati, D Capodanno, F Franchi, F Rollini, D D'Amario, ... The Lancet 397 (10283), 1470-1483, 2021 | 169 | 2021 |
| Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial RF Storey, DJ Angiolillo, MP Bonaca, MR Thomas, HM Judge, F Rollini, ... Journal of the American College of Cardiology 67 (10), 1145-1154, 2016 | 139 | 2016 |
| Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention … F Franchi, F Rollini, A Rivas, M Wali, M Briceno, M Agarwal, Z Shaikh, ... Circulation 139 (14), 1661-1670, 2019 | 131 | 2019 |
| Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study F Rollini, F Franchi, J Hu, M Kureti, N Aggarwal, A Durairaj, Y Park, ... Journal of the American College of Cardiology 67 (17), 1994-2004, 2016 | 128 | 2016 |
| Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy PE Empey, JM Stevenson, S Tuteja, KW Weitzel, DJ Angiolillo, ... Clinical Pharmacology & Therapeutics 104 (4), 664-674, 2018 | 108 | 2018 |
| Antithrombotic therapy for patients with STEMI undergoing primary PCI F Franchi, F Rollini, DJ Angiolillo Nature Reviews Cardiology 14 (6), 361-379, 2017 | 106 | 2017 |
| Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials M Galli, S Benenati, F Franchi, F Rollini, D Capodanno, G Biondi-Zoccai, ... European heart journal 43 (10), 959-967, 2022 | 104 | 2022 |
| Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in … F Franchi, F Rollini, N Aggarwal, J Hu, M Kureti, A Durairaj, VE Duarte, ... Circulation 134 (11), 780-792, 2016 | 90 | 2016 |
| Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention … F Franchi, F Rollini, JR Cho, M Bhatti, C DeGroat, E Ferrante, EC Dunn, ... Cardiovascular Interventions 8 (11), 1457-1467, 2015 | 79 | 2015 |
| Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy JY Moon, F Franchi, F Rollini, DJ Angiolillo Progress in cardiovascular diseases 60 (4-5), 478-490, 2018 | 75 | 2018 |
| A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective … F Rollini, F Franchi, JR Cho, C DeGroat, M Bhatti, A Muniz-Lozano, ... European heart journal 37 (35), 2722-2730, 2016 | 67 | 2016 |
| Role of genetic testing in patients undergoing percutaneous coronary intervention JY Moon, F Franchi, F Rollini, JR Rivas Rios, M Kureti, LH Cavallari, ... Expert review of clinical pharmacology 11 (2), 151-164, 2018 | 66 | 2018 |
| Institutional profile: University of Florida health personalized medicine program LH Cavallari, KW Weitzel, AR Elsey, X Liu, SA Mosley, DM Smith, ... Pharmacogenomics 18 (5), 421-426, 2017 | 66 | 2017 |
| Cangrelor: a review on pharmacology and clinical trial development F Franchi, F Rollini, A Muniz-Lozano, J Rae Cho, DJ Angiolillo Expert Review of Cardiovascular Therapy 11 (10), 1279-1291, 2013 | 64 | 2013 |
| Platelet function profiles in patients with diabetes mellitus F Rollini, F Franchi, A Muñiz-Lozano, DJ Angiolillo Journal of cardiovascular translational research 6, 329-345, 2013 | 64 | 2013 |
| Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice A Muñiz-Lozano, F Rollini, F Franchi, DJ Angiolillo Therapeutic Advances in Cardiovascular Disease 7 (4), 197-213, 2013 | 63 | 2013 |
